{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"76"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"137"}],"units":"Participants"}],"description":"Hematologic response is defined as the percentage of participants in complete hematologic response (defined as the following present for at least 4 weeks: WBC count \\<10 x 109/L, Platelet count \\<450 x 109/L, Basophils \\<5%, No blasts and promyelocytes in peripheral blood, Myelocytes + metamyelocytes \\< 5% in peripheral blood, No evidence of extramedullary disease, including spleen and liver).\n\nHematological response was a primary outcome measure for Arm CML-AP with prior imatinib only.","groups":[{"description":"Adult participants Ph+ CML-AP without prior TKI treatment with either resistant / intolerant to Imatinib received 400 mg Nilotinib orally twice daily up to the end of treatment (September-2012).","id":"OG000","title":"CML-AP With Prior Imatinib Only"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Full Analysis Set (FAS): All participants who received at least one dose of study medication.","reportingStatus":"POSTED","timeFrame":"Up to End of the Treatment (Approximately 7.5 years)","title":"Number of Participants Confirmed Overall Hematological Response (Phase II)","type":"PRIMARY","unitOfMeasure":"Participants"}